Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.75 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 5/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.63 |
| ▸ | CDK9 | P50750 | 2/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553781 | 0.88 | FLT3 (0.60) | FLT3EGFRKDRPTK2JAK2 | |
| SCHEMBL26980297 | 0.87 | JAK2 (0.61) | FLT3EGFRKDRPTK2JAK2 | |
| SCHEMBL4499528 | 0.86 | FLT3 (0.69) | FLT3KDRPTK2JAK2CCNT1 | |
| SCHEMBL4518391 | 0.86 | FLT3 (1.00) | FLT3EGFRCCNT1CDK9HDAC1 | |
| SCHEMBL17542602 | 0.84 | FLT3 (0.58) | FLT3EGFRKDRPTK2JAK2 | |
| SCHEMBL29174371 | 0.84 | EGFR (0.62) | FLT3EGFRKDRPTK2CCNT1 | |
| SCHEMBL29896599 | 0.83 | CCNT1 (0.65) | FLT3EGFRCCNT1CDK9HDAC1 | |
| SCHEMBL29896672 | 0.83 | CCNT1 (0.65) | FLT3EGFRCCNT1CDK9HDAC1 | |
| SCHEMBL29174394 | 0.83 | CCNT1 (0.65) | FLT3EGFRCCNT1CDK9HDAC1 | |
| SCHEMBL29174415 | 0.83 | CCNT1 (0.65) | FLT3EGFRCCNT1CDK9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | FLT3 91/4885EGFR 598/4885KDR 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.